Stock 4883 MODALIS THERAPEUTICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-16 am EDT 		5-day change 1st Jan Change
70 JPY 0.00% Intraday chart for Modalis Therapeutics Corporation 0.00% -43.55%
Jul. 10 Modalis Therapeutics Partners Genixcure for Alzheimer's Treatment MT
Jul. 10 Modalis and GENIXCURE Enter into Memorandum of Understanding for Research Collaboration to Develop Next-Generation Therapeutics CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
BU
Modalis Announces updated strategic plan and business consolidation of US operation
AQ
Modalis Announces Partnership with Ginkgo Bioworks
AQ
Modalis Announces Partnership with Ginkgo Bioworks
BU
Modalis and JCR Pharmaceuticals enter into joint research agreement
BU
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting
BU
Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
PU
Modalis Therapeutics : Notice Regarding a Patent Allowance for ‘Method for treating muscular dystrophy by targeting utrophin gene’ in the USA
PU
Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)
PU
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting
BU
Modalis Therapeutics : to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines at the ASGCT Annual Meeting
PU
Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)
PU
Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
PU
Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential
PU
Modalis Therapeutics : Announcement of Issuance of Stock Options (Share Acquisition Rights)
PU
Modalis Therapeutics : Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
PU
Modalis Therapeutics : Announces Termination of Research Collaboration on MDL-204
PU
Modalis Therapeutics : Q＆A regarding Notice of Modalis Announces Termination of a Research Collaboration on MDL-204
PU
Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential
PU
Consolidated Financial Results for the Nine Months Ended September 30, 2021[Japanese GAAP]
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4883 Stock
  4. News Modalis Therapeutics Corporation
  5. Press Releases